{"id":"rivastigmine","brandName":"Exelon","genericName":"rivastigmine","companyId":"novartis","companyName":"Novartis","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"Acetylcholinesterase, Cholinesterase, Acetylcholine receptor subunit epsilon"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"2213 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"1711 reports"},{"date":"","signal":"HALLUCINATION","source":"FDA FAERS","actionTaken":"1395 reports"},{"date":"","signal":"CONFUSIONAL STATE","source":"FDA FAERS","actionTaken":"1295 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"925 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"907 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"853 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"793 reports"},{"date":"","signal":"GAIT DISTURBANCE","source":"FDA FAERS","actionTaken":"725 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"693 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"47%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"31%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"19%","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"21%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Increased Sweating","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Tremor","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Syncope","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Decreased Weight","drugRate":"3%","severity":"common","organSystem":""}],"contraindications":["Anorexia nervosa","Asthma","Atrioventricular block","Chronic obstructive lung disease","Conduction disorder of the heart","Diarrhea","Extrapyramidal disease","Gastrointestinal hemorrhage","Gastrointestinal ulcer","Nausea","Neuromuscular block, function","Parkinsonism","Seizure disorder","Sick sinus syndrome","Urinary tract obstruction","Vomiting","Weight loss"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":["NCT03840837","NCT00622713","NCT01856738","NCT00835159","NCT01146041","NCT00219245","NCT00624663","NCT00102284","NCT01025466","NCT04366518","NCT06702124","NCT02374567","NCT01670526","NCT00000174","NCT01023425","NCT00018278","NCT00766363","NCT01073319","NCT00880412","NCT05768126","NCT02187276","NCT01951118","NCT03959124","NCT01696591","NCT04731311","NCT00561392","NCT02989402","NCT01348282","NCT01380288","NCT05321680","NCT00104442","NCT04226248","NCT00627848","NCT00428389","NCT03573050","NCT01084135","NCT03659435","NCT02703636","NCT00158210","NCT00234637","NCT00522015","NCT00704301","NCT01948791","NCT00099216","NCT07464340","NCT02063269","NCT00423085","NCT00988117","NCT01944436","NCT00599287"],"indications":{"approved":[{"name":"Alzheimer's disease","diseaseId":"alzheimer's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Dementia associated with Parkinson's Disease","diseaseId":"dementia-associated-with-parkinson's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT03840837","phase":"Phase 4","title":"Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","isPivotal":false,"enrollment":31,"indication":"Parkinson Disease, Parkinson Disease Dementia","completionDate":"2020-04-01"},{"nctId":"NCT00622713","phase":"Phase 4","title":"A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE 10-26)","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":228,"indication":"Alzheimer's Disease","completionDate":"2009-01"},{"nctId":"NCT01856738","phase":"Phase 4","title":"Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","isPivotal":false,"enrollment":91,"indication":"Parkinson's Disease","completionDate":"2018-09"},{"nctId":"NCT00835159","phase":"Phase 4","title":"Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial","status":"COMPLETED","sponsor":"NYU Langone Health","isPivotal":false,"enrollment":30,"indication":"Delirium, Postoperative Cognitive Dysfunction","completionDate":"2010-10"},{"nctId":"NCT01146041","phase":"Phase 1","title":"Randomized, 2-Way Crossover, Bioequivalence Study of Rivastigmine 1.5 mg Capsules and Exelon Administered as 1 x 1.5 mg Capsule in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":44,"indication":"Healthy","completionDate":"2004-04"},{"nctId":"NCT00219245","phase":"Phase 4","title":"A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/D","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":157,"indication":"Traumatic Brain Injury With Persistent Cognitive Deficits","completionDate":"2005-01"},{"nctId":"NCT00624663","phase":"NA","title":"A Double-Blind, Placebo-controlled Crossover Study to Assess the Pharmacokinetic Profile and the Physiological and Behavioral Effects of Repeat Rivastigmine (Exelon®) Administration in Young Healthy M","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","isPivotal":false,"enrollment":15,"indication":"Rivastigmine Toxicity","completionDate":"2009-04"},{"nctId":"NCT00102284","phase":"Phase 4","title":"Improved Language Acquisition Through Neuromodulation, Project Stage Ia","status":"TERMINATED","sponsor":"University Hospital Muenster","isPivotal":false,"enrollment":100,"indication":"Healthy","completionDate":"2005-04"},{"nctId":"NCT01025466","phase":"Phase 4","title":"A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Inha University Hospital","isPivotal":false,"enrollment":206,"indication":"Alzheimer's Disease","completionDate":"2010-04"},{"nctId":"NCT04366518","phase":"EARLY/Phase 1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","isPivotal":false,"enrollment":35,"indication":"Hallucinations, Auditory, Psychosis","completionDate":"2032-08"},{"nctId":"NCT06702124","phase":"Phase 3","title":"Effects of Dopaminergic Therapy in Patients with Alzheimer's Disease: a 24 Weeks Prospective, Randomized, Double-blind, Placebo-controlled, Parallel Group, International, Multi-center Phase III Study ","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","isPivotal":true,"enrollment":348,"indication":"Alzheimer Disease","completionDate":"2026-04"},{"nctId":"NCT02374567","phase":"Phase 3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","isPivotal":true,"enrollment":407,"indication":"Dementia, Depression","completionDate":"2017-06-28"},{"nctId":"NCT01670526","phase":"Phase 3","title":"Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","isPivotal":true,"enrollment":94,"indication":"Traumatic Brain Injury, Cognitive Impairment","completionDate":"2017-09"},{"nctId":"NCT00000174","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Novartis","isPivotal":true,"enrollment":0,"indication":"Alzheimer Disease, Cognition Disorders","completionDate":""},{"nctId":"NCT01023425","phase":"NA","title":"Comparative Assessment of Clinical Efficacy of Donepezil Between the Naive Group and the Switching Group","status":"COMPLETED","sponsor":"Samsung Medical Center","isPivotal":false,"enrollment":72,"indication":"Alzheimer's Disease, Dementia","completionDate":"2009-04"},{"nctId":"NCT00018278","phase":"Phase 4","title":"Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","isPivotal":false,"enrollment":0,"indication":"Alzheimer Disease","completionDate":"2001-09"},{"nctId":"NCT00766363","phase":"Phase 1","title":"A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients W","status":"COMPLETED","sponsor":"FORUM Pharmaceuticals Inc","isPivotal":false,"enrollment":49,"indication":"Alzheimer's Disease, Central Nervous System Diseases","completionDate":"2009-03"},{"nctId":"NCT01073319","phase":"Phase 1","title":"Rivastigmine as a Treatment for Methamphetamine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","isPivotal":false,"enrollment":17,"indication":"Methamphetamine Dependence, Substance Abuse","completionDate":"2010-07"},{"nctId":"NCT00880412","phase":"Phase 2","title":"A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid","status":"COMPLETED","sponsor":"Exonhit","isPivotal":false,"enrollment":197,"indication":"Alzheimer's Disease","completionDate":"2009-08"},{"nctId":"NCT05768126","phase":"Phase 4","title":"Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine","status":"RECRUITING","sponsor":"UMC Utrecht","isPivotal":false,"enrollment":100,"indication":"Depressive Disorder","completionDate":"2026-01"},{"nctId":"NCT02187276","phase":"N/A","title":"The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer Disease and Mixed Dementia: a Naturalistic Study","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","isPivotal":false,"enrollment":129,"indication":"Alzheimer Disease, Late Onset","completionDate":"2013-03"},{"nctId":"NCT01951118","phase":"Phase 4","title":"Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":121,"indication":"Alzheimer Disease, Mild Cognitive Impairment","completionDate":"2019-05"},{"nctId":"NCT03959124","phase":"NA","title":"The Effect of Deep Brain Stimulation on Memory Network and Neurological Function of Alzheimer's Disease","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","isPivotal":false,"enrollment":30,"indication":"Alzheimer Disease, Dementia, Alzheimer Type","completionDate":"2021-09-30"},{"nctId":"NCT01696591","phase":"N/A","title":"The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD","status":"UNKNOWN","sponsor":"Duk Lyul Na","isPivotal":false,"enrollment":14,"indication":"Alzheimer Disease, Dementia","completionDate":"2013-09"},{"nctId":"NCT04731311","phase":"NA","title":"Telerehabilitation Combining Virtual Reality Adaptable Games and Drug Therapy for Early Alzheimer's Disease - Usability","status":"COMPLETED","sponsor":"Bright Cloud International Corp","isPivotal":false,"enrollment":4,"indication":"Alzheimer Disease, Healthy Aging","completionDate":"2021-09-07"},{"nctId":"NCT00561392","phase":"Phase 4","title":"A 24-week, Multi-center, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE10-26)","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":208,"indication":"Alzheimer's Disease","completionDate":"2008-11"},{"nctId":"NCT02989402","phase":"Phase 4","title":"A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Pat","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":100,"indication":"Alzheimer's Disease","completionDate":"2022-12-08"},{"nctId":"NCT01348282","phase":"Phase 4","title":"Exploratory Controlled Prospective Randomized Trial to Compare the Efficacy and Safety of Two Different Pharmacology Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","isPivotal":false,"enrollment":33,"indication":"Neurocognitive Disturbance, HIV Infection","completionDate":"2014-03"},{"nctId":"NCT01380288","phase":"NA","title":"Changes of Cognitive Function in Patients With Mild to Moderate Alzheimer's Disease Associated With or Without White Matter Changes After Rivastigmine Patch Therapy - Multi-center, Prospective, Open-l","status":"COMPLETED","sponsor":"Dong-A University","isPivotal":false,"enrollment":300,"indication":"Alzheimer's Disease","completionDate":"2017-12-31"},{"nctId":"NCT05321680","phase":"NA","title":"Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD): a Randomized Clinical Trial and Cost-utility Analysis","status":"COMPLETED","sponsor":"Centro Hospitalar De São João, E.P.E.","isPivotal":false,"enrollment":16,"indication":"Dementia","completionDate":"2022-03-20"},{"nctId":"NCT00104442","phase":"Phase 4","title":"Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":80,"indication":"Alzheimer's Disease","completionDate":"2006-04"},{"nctId":"NCT04226248","phase":"Phase 3","title":"CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease: A Phase 3 Randomised, Double-blind Placebo-controlled Trial of Rivastigmine to Prevent Falls in Parkinson's Disease.","status":"COMPLETED","sponsor":"University of Bristol","isPivotal":true,"enrollment":600,"indication":"Parkinson Disease","completionDate":"2025-07-24"},{"nctId":"NCT00627848","phase":"NA","title":"Effect of Rivastigmine on FMRI in Mild Alzheimer's Disease","status":"COMPLETED","sponsor":"Kuopio University Hospital","isPivotal":false,"enrollment":20,"indication":"Alzheimer' Disease","completionDate":"2008-12"},{"nctId":"NCT00428389","phase":"Phase 3","title":"A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial ","status":"COMPLETED","sponsor":"Novartis","isPivotal":true,"enrollment":262,"indication":"Alzheimer's Disease","completionDate":"2008-02"},{"nctId":"NCT03573050","phase":"Phase 1","title":"Multiple Dose Crossover Comparative Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared With Exelon® Transdermal Patch With a Release Rate of 13.3 mg/24 Hours in Healthy ","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","isPivotal":false,"enrollment":36,"indication":"Bioequivalence","completionDate":"2018-07-05"},{"nctId":"NCT01084135","phase":"Phase 1","title":"A 20-Week Double-Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Rivastigmine in Children (Ages 10-18) With Down Syndrome","status":"COMPLETED","sponsor":"Duke University","isPivotal":false,"enrollment":42,"indication":"Down Syndrome","completionDate":"2014-02"},{"nctId":"NCT03659435","phase":"Phase 1","title":"Open, Randomized, 2-period, 2-sequence, Cross-over Relative Bioavailability Study to Investigate the Pharmacokinetics and to Assess the Bioequivalence of a Rivastigmine Test Patch Formulation 9.5 mg/2","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","isPivotal":false,"enrollment":58,"indication":"Bioequivalence","completionDate":"2018-11-28"},{"nctId":"NCT02703636","phase":"Phase 4","title":"A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch With 1-step Titration in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10 - ","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":118,"indication":"Mild to Moderate Alzheimer's Disease","completionDate":"2018-05-07"},{"nctId":"NCT00158210","phase":"Phase 1","title":"Double-Blind Randomized Placebo Controlled Trial of Rivastigmine (Excelon) as a Potential Medication for Methamphetamine Abuse","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","isPivotal":false,"enrollment":18,"indication":"Substance-Related Disorders","completionDate":"2007-03"},{"nctId":"NCT00234637","phase":"Phase 4","title":"An Open-label Study to Evaluate the Efficacy and Safety of add-on Memantine [5-10 mg b.i.d (10-20 mg/Day)] to Rivastigmine [1.5-6 mg b.i.d. (3-12 mg/Day)] Treatment in Patients With Alzheimer's Diseas","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":204,"indication":"Alzheimer's Disease","completionDate":"2005-06"},{"nctId":"NCT00522015","phase":"Phase 2","title":"Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","isPivotal":false,"enrollment":20,"indication":"Progressive Supranuclear Palsy, Dementia","completionDate":"2010-02"},{"nctId":"NCT00704301","phase":"Phase 4","title":"Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial","status":"TERMINATED","sponsor":"UMC Utrecht","isPivotal":false,"enrollment":104,"indication":"Delirium","completionDate":"2010-05"},{"nctId":"NCT01948791","phase":"Phase 4","title":"16 Weeks Interventional Study on Titration and Dose/Efficacy Assessment of Exelon (Rivastigmine) in Chinese Alzheimer's Disease Patients (INSTINCT)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":222,"indication":"Alzheimer's Disease","completionDate":"2015-09"},{"nctId":"NCT00099216","phase":"Phase 3","title":"Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":708,"indication":"Vascular Dementia","completionDate":"2005-11"},{"nctId":"NCT07464340","phase":"Phase 1","title":"Bioequivalence and Adhesion Assessment Between Two Rivastigmine Transdermal Patch Formulations","status":"COMPLETED","sponsor":"Zodiac Produtos Farmaceuticos S.A.","isPivotal":false,"enrollment":68,"indication":"Bioequivalence Study in Healthy Subjects","completionDate":"2023-07-03"},{"nctId":"NCT02063269","phase":"NA","title":"Differences of Functional Changes in Brain by Rivastigmine According to Butyrylcholinesterase Alleles in Alzheimer's Disease Patients(Rivastigmine, Imaging, and BuChE in AD: RIBA)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":70,"indication":"Alzheimer's Disease","completionDate":"2017-06"},{"nctId":"NCT00423085","phase":"Phase 3","title":"A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":859,"indication":"Alzheimer's Disease","completionDate":"2010-04"},{"nctId":"NCT00988117","phase":"Phase 4","title":"The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)","status":"COMPLETED","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":15,"indication":"Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems","completionDate":"2011-04"},{"nctId":"NCT01944436","phase":"N/A","title":"Lewy Body Spectrum Disorders: Investigating Neuropsychiatric Benefit and Adverse Effects in Response to Cholinesterase Inhibitors Using Genetics and Brain SPECT","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","isPivotal":false,"enrollment":57,"indication":"Lewy Body Disease","completionDate":"2016-01"},{"nctId":"NCT00599287","phase":"Phase 3","title":"Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients: a Randomized, Mono-blind Pilot Trial","status":"TERMINATED","sponsor":"UMC Utrecht","isPivotal":true,"enrollment":80,"indication":"Delirium","completionDate":"2008-05"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1960/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$72","description":"RIVASTIGMINE 1.5 MG CAPSULE","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-11-17T00:00:00.000Z","mah":"ALEMBIC PHARMS LTD","brand_name_local":null,"application_number":"ANDA091689"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-11-02T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":"NDA022083"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-02-13T00:00:00.000Z","mah":"CADILA PHARMS LTD","brand_name_local":null,"application_number":"ANDA203844"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-04-04T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":null,"application_number":"ANDA204572"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-01-22T00:00:00.000Z","mah":"AMNEAL PHARMS","brand_name_local":null,"application_number":"ANDA207308"},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":"EMEA/H/C/000169"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Exelon","application_number":null}],"trialStats":{"total":0,"withResults":0},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=rivastigmine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:18:54.127354+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:18:59.024362+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:18:53.252803+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rivastigmine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:18:59.484380+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:51.133517+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:51.133546+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:19:00.976147+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cholinesterases; ACHE & BCHE inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:00.537815+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL636/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:00.188745+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA091689","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:18:51.133550+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:19:04.011491+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL636"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}